Matthew W Jenner

6PUBLICATIONS
31CO-AUTHORS
Medical mycologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 20, 2025
Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling.

Sina A Beer, David A Cairns, Charlotte Pawlyn

|Dec 09, 2024
Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS.

Ola Landgren, Ajai Chari, Yael C Cohen

|Jun 14, 2023
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.

Martin F Kaiser, Andrew Hall, Katrina Walker

|Dec 23, 2022
Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial.

Aikaterini Panopoulou, David A Cairns, Amy Holroyd

|Apr 04, 2022
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.

Ruth M de Tute, Charlotte Pawlyn, David A Cairns

|Jan 11, 2021
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.

Graham H Jackson, Charlotte Pawlyn, David A Cairns

Pageof 1

Frequent Collaborators

5 joint publications

Martin F Kaiser

4 joint publications

Charlotte Pawlyn

4 joint publications

Gordon Cook

3 joint publications

David A Cairns